Skip to main content
Top
Published in: Malaria Journal 1/2010

Open Access 01-12-2010 | Research

Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols

Authors: Erin Milner, William McCalmont, Jayendra Bhonsle, Diana Caridha, Jose Cobar, Sean Gardner, Lucia Gerena, Duane Goodine, Charlotte Lanteri, Victor Melendez, Norma Roncal, Jason Sousa, Peter Wipf, Geoffrey Stuart Dow

Published in: Malaria Journal | Issue 1/2010

Login to get access

Abstract

Background

The clinical utility for mefloquine has been eroded due to its association with adverse neurological effects. Better-tolerated alternatives are required. The objective of the present study was the identification of lead compounds that are as effective as mefloquine, but exhibit physiochemical properties likely to render them less susceptible to passage across the blood-brain barrier.

Methods

A library of drug-like non-piperidine analogs of mefloquine was synthesized. These compounds are diverse in structure and physiochemical properties. They were screened in appropriate in vitro assays and evaluated in terms of their potential as lead compounds. The correlation of specific structural attributes and physiochemical properties with activity was assessed.

Results

The most potent analogs were low molecular weight unconjugated secondary amines with no heteroatoms in their side-chains. However, these compounds were more metabolically labile and permeable than mefloquine. In terms of physiochemical properties, lower polar surface area, lower molecular weight, more freely rotatable bonds and fewer H-bond acceptors were associated with greater potency. There was no such relationship between activity and LogP, LogD or the number of hydrogen bond donors (HBDs). The addition of an H-bond donor to the side-chain yielded a series of active diamines, which were as metabolically stable as mefloquine but showed reduced permeability.

Conclusions

A drug-like library of non-piperidine analogs of mefloquine was synthesized. From amongst this library an active lead series of less permeable, but metabolically stable, diamines was identified.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dow GS, Magill AJ, Ohrt C: Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag. 2008, 4: Dow GS, Magill AJ, Ohrt C: Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag. 2008, 4:
2.
go back to reference Schellenberg D, Cisse B, Mendendez C: The IPTi Consortium: research for policy and action. Trends Parasitol. 2006, 22: 296-300. 10.1016/j.pt.2006.05.006.CrossRefPubMed Schellenberg D, Cisse B, Mendendez C: The IPTi Consortium: research for policy and action. Trends Parasitol. 2006, 22: 296-300. 10.1016/j.pt.2006.05.006.CrossRefPubMed
3.
go back to reference Shanks GD, Magill AJ, Freedman DO, Keystone JS, Bradley DJ, Steffen R: Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. Am J Trop Med Hyg. 2007, 77: 1-2.PubMed Shanks GD, Magill AJ, Freedman DO, Keystone JS, Bradley DJ, Steffen R: Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. Am J Trop Med Hyg. 2007, 77: 1-2.PubMed
4.
go back to reference Rendi-Wagner P, Noedl H, Wernsdorfer WH, Weidermann G, Mikolasek A, Kollaristch H: Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002, 81: 167-173. 10.1016/S0001-706X(01)00210-8.CrossRefPubMed Rendi-Wagner P, Noedl H, Wernsdorfer WH, Weidermann G, Mikolasek A, Kollaristch H: Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002, 81: 167-173. 10.1016/S0001-706X(01)00210-8.CrossRefPubMed
5.
go back to reference Caridha A, Yourick D, Cabezas M, Wolf L, Hudson TH, Dow GS: Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin. Antimicrob Agent Chemother. 2008, 52: 684-693. 10.1128/AAC.00874-07.CrossRef Caridha A, Yourick D, Cabezas M, Wolf L, Hudson TH, Dow GS: Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin. Antimicrob Agent Chemother. 2008, 52: 684-693. 10.1128/AAC.00874-07.CrossRef
6.
go back to reference Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, Park M, Smith K, Cannard K: Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agent Chemother. 2006, 50: 1045-1053. 10.1128/AAC.50.3.1045-1053.2006.CrossRef Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, Park M, Smith K, Cannard K: Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agent Chemother. 2006, 50: 1045-1053. 10.1128/AAC.50.3.1045-1053.2006.CrossRef
7.
go back to reference CLARK DE: In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003, 8: 927-933. 10.1016/S1359-6446(03)02827-7.CrossRefPubMed CLARK DE: In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003, 8: 927-933. 10.1016/S1359-6446(03)02827-7.CrossRefPubMed
8.
go back to reference Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LL, Serabit-Singh CJ, Adkinson KK, Polli JW: Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Therap. 2002, 303: 1029-1037. 10.1124/jpet.102.039255.CrossRef Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LL, Serabit-Singh CJ, Adkinson KK, Polli JW: Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Therap. 2002, 303: 1029-1037. 10.1124/jpet.102.039255.CrossRef
9.
go back to reference Pardridge WM: Transport of small molecules through blood-brain barrier: biology and methodology. Adv Drug Deliv Rev. 1995, 15: 5-36. 10.1016/0169-409X(95)00003-P.CrossRef Pardridge WM: Transport of small molecules through blood-brain barrier: biology and methodology. Adv Drug Deliv Rev. 1995, 15: 5-36. 10.1016/0169-409X(95)00003-P.CrossRef
10.
go back to reference Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998, 70: 1781-1792.CrossRefPubMed Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998, 70: 1781-1792.CrossRefPubMed
11.
go back to reference Price RN, Uhleman AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004, 364: 438-447. 10.1016/S0140-6736(04)16767-6.PubMedCentralCrossRefPubMed Price RN, Uhleman AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004, 364: 438-447. 10.1016/S0140-6736(04)16767-6.PubMedCentralCrossRefPubMed
12.
go back to reference Dow GS, Heady TN, Bhattarchargee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldia N III, Roncal N, Shearer T, Smith PL, Tungtaeng A, Wolf L, Cabezas M, Yourick D, Smith KS: Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrob Agents Chemother. 2006, 50: 4132-4143. 10.1128/AAC.00631-06.PubMedCentralCrossRefPubMed Dow GS, Heady TN, Bhattarchargee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldia N III, Roncal N, Shearer T, Smith PL, Tungtaeng A, Wolf L, Cabezas M, Yourick D, Smith KS: Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrob Agents Chemother. 2006, 50: 4132-4143. 10.1128/AAC.00631-06.PubMedCentralCrossRefPubMed
13.
go back to reference Milner E, McCalmont W, Bhonsle J, Caridha C, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tangtaeng A, Wipf P, Dow GS: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett. 2010 Milner E, McCalmont W, Bhonsle J, Caridha C, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tangtaeng A, Wipf P, Dow GS: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett. 2010
14.
go back to reference Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000, 44: 235-249. 10.1016/S1056-8719(00)00107-6.CrossRefPubMed Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000, 44: 235-249. 10.1016/S1056-8719(00)00107-6.CrossRefPubMed
15.
go back to reference Kerns EH, Di L: Drug-like properties: concepts, structure design and methods. 2008, Burlington, MA, Elsevier Inc, Dow GS, Chen Y, Andrews KT, Caridha D, Gerena L, Gettayacamin M, Johnson J, Li Q, Melendez V, Obaldia N III, Tran TN and Kozikowski A:Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob Agents Chemother 2008 52:3467-3477. Kerns EH, Di L: Drug-like properties: concepts, structure design and methods. 2008, Burlington, MA, Elsevier Inc, Dow GS, Chen Y, Andrews KT, Caridha D, Gerena L, Gettayacamin M, Johnson J, Li Q, Melendez V, Obaldia N III, Tran TN and Kozikowski A:Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob Agents Chemother 2008 52:3467-3477.
16.
go back to reference Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979, 16: 710-8.PubMedCentralCrossRefPubMed Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979, 16: 710-8.PubMedCentralCrossRefPubMed
17.
go back to reference Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE: In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother. 1985, 27: 525-30.PubMedCentralCrossRefPubMed Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE: In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother. 1985, 27: 525-30.PubMedCentralCrossRefPubMed
18.
go back to reference Gillespie JJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CF, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward S, Weiss SM, Williamson DS: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008, 18: 2916-2919. 10.1016/j.bmcl.2008.03.075.CrossRefPubMed Gillespie JJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CF, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward S, Weiss SM, Williamson DS: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008, 18: 2916-2919. 10.1016/j.bmcl.2008.03.075.CrossRefPubMed
19.
go back to reference Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misar A, Pratt RM, Revell D, Upton R, Dourish CT: Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology. 2003, 61: S101-106.CrossRefPubMed Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misar A, Pratt RM, Revell D, Upton R, Dourish CT: Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology. 2003, 61: S101-106.CrossRefPubMed
20.
go back to reference Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ: Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2005, 288: 349-359. 10.1016/j.ijpharm.2004.10.007.CrossRefPubMed Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ: Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2005, 288: 349-359. 10.1016/j.ijpharm.2004.10.007.CrossRefPubMed
21.
go back to reference Go ML, Ngiam TL: Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents. Chem Pharm Bull. 1997, 45: 2055-2060.CrossRefPubMed Go ML, Ngiam TL: Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents. Chem Pharm Bull. 1997, 45: 2055-2060.CrossRefPubMed
22.
go back to reference Zidovetzki R, Sherman IW, Attiya A, De Boeck H: A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers. Mol Biochem Parasitol. 1989, 35: 199-207. 10.1016/0166-6851(89)90206-5.CrossRefPubMed Zidovetzki R, Sherman IW, Attiya A, De Boeck H: A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers. Mol Biochem Parasitol. 1989, 35: 199-207. 10.1016/0166-6851(89)90206-5.CrossRefPubMed
Metadata
Title
Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols
Authors
Erin Milner
William McCalmont
Jayendra Bhonsle
Diana Caridha
Jose Cobar
Sean Gardner
Lucia Gerena
Duane Goodine
Charlotte Lanteri
Victor Melendez
Norma Roncal
Jason Sousa
Peter Wipf
Geoffrey Stuart Dow
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2010
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-9-51

Other articles of this Issue 1/2010

Malaria Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.